News coverage about Merck & Co. (NYSE:MRK) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merck & Co. earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.4019892200182 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

A number of equities research analysts have recently weighed in on the company. BMO Capital Markets reiterated a “buy” rating and issued a $72.00 price target on shares of Merck & Co. in a report on Friday, September 8th. Credit Suisse Group reiterated an “outperform” rating and issued a $74.00 price target (down from $75.00) on shares of Merck & Co. in a report on Tuesday, September 5th. Cowen and Company reiterated a “hold” rating and issued a $70.00 price target on shares of Merck & Co. in a report on Friday, September 1st. Jefferies Group LLC reiterated a “sell” rating and issued a $52.00 price target on shares of Merck & Co. in a report on Sunday, August 20th. Finally, HSBC Holdings plc upgraded Merck & Co. from a “reduce” rating to a “hold” rating in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $69.81.

Shares of Merck & Co. (NYSE:MRK) traded down 0.08% during mid-day trading on Friday, hitting $64.55. The firm has a market cap of $176.05 billion, a price-to-earnings ratio of 34.95 and a beta of 0.80. The firm’s 50 day moving average price is $64.27 and its 200-day moving average price is $63.68. Merck & Co. has a one year low of $58.29 and a one year high of $66.80.

Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. Merck & Co. had a return on equity of 19.69% and a net margin of 19.65%. The business had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. During the same period in the previous year, the firm earned $0.93 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. Equities analysts expect that Merck & Co. will post $3.87 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 6th. Investors of record on Friday, September 15th were paid a dividend of $0.47 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.91%. Merck & Co.’s dividend payout ratio (DPR) is presently 76.11%.

TRADEMARK VIOLATION WARNING: “Merck & Co. (MRK) Receives Coverage Optimism Score of 0.08” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/merck-co-mrk-receives-coverage-optimism-score-of-0-08/1618453.html.

Merck & Co. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Insider Buying and Selling by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.